
Dr. Antonio Calles 🫁🚭
24.5K posts

Dr. Antonio Calles 🫁🚭
@Tony_Calles
Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón ⎪@myESMO Faculty 🫁 ⎪#endlungcancer #lcsm




RECITE: In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16). Full trial results: nejm.org/doi/full/10.10… Editorial: Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia nejm.org/doi/full/10.10…

With European Lung Cancer Congress 2026 late-breaking titles out, we asked leading AI models to identify the most anticipated Lung Cancer trials, here’s their combined ranking. NeoADAURA and TROPION-Lung17 emerge at the top of the list. This highlights broad interest across perioperative EGFR strategies in resectable NSCLC, next-generation ADCs such as datopotamab deruxtecan, evolving EGFR combination approaches, and new maintenance or post-IO strategies in SCLC and NSCLC. Together, these studies reflect how the field is pushing forward on earlier-stage intervention, targeted combinations, and ADC-driven treatment backbones heading into ELCC 2026. Which lung cancer study are you watching most closely? Explore more insights and conference data from #ELCC26 👉 t.ly/ClEtq #LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #EGFR #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @StephenVLiu | @Tony_Calles | @FordePatrick | @ADesaiMD | @lungoncdoc



ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors in @ESMO_Open. Evidence-based consensus statements providing guidance on the safety of combining RT with EGFR, ALK, or BRAF/MEK inhibitors. esmoopen.com/article/S2059-…



@LungConsultant – data driving accountability and improvement. #BTOG26













Registered for #BTOG26? The BTOG 2026 App is now available to download in the app store. Enter the email address you registered with and set a password – this will be different to your member login.





Xin Lu, PhD, describes the scientific foundations of a study of rezatapopt, which targets a variant form of p53, to treat patients with solid tumors. Learn about the science behind the study in the editorial “Restoring Function to a Variant of p53 in Solid Tumors,” from @Ludwig_Cancer: nej.md/3N0pQW8



